Palantir CTO sells $64.9 million of shares; NHS pilots unused
- Bad news: Chief technology officer Sankar sold about $64.9 million of shares over two days under a pre-set 10b5-1 plan, after the 85% rise in equity awards.
- Bad news: The two flagship NHS Cancer 360 success cases had zero logged-in users over 12 months, so low take-up of one product is a real weakness.
Read the full notes
Two negative signals have landed together at Palantir. First, chief technology officer Sankar sold 384,680 shares over two days, about $64.9 million, under a pre-set 10b5-1 plan. Set against the 85% rise in equity awards on 2 Nov, the pattern of receiving shares and then selling them is worth tracking.
Read more
Second, the NHS Cancer 360 pilot, four years in, is officially used by only 5 to 6 trusts, and in Freedom of Information replies the two flagship success cases had zero logged-in users over the past 12 months. The weakness of the Federal Data Platform is low penetration of a single product, not just political resistance.
Key evidence
- Form 4 filed on 13 Nov (checked against the original on EDGAR): on 10 Nov Sankar converted 300,000 Class B shares to Class A and sold them on the open market (C to S), about $50.1 million; on 11 Nov he did the same with 84,680 shares, about $14.8 million
- Total over the two days: 384,680 shares, about $64.9 million; the 10b5-1 plan was set up on 10 Aug (nearly three months before earnings)
- After the sales he directly holds about 858,000 Class A shares (Class B and trust holdings not included)
- Classified as S (voluntary sale), not F (tax withholding), but executed under a pre-set plan
- An earlier Form 144 gave the source as RSUs, but what was actually sold was converted Class B stock (which carries super-voting rights and dilutes the founding team's voting control, though 380,000 shares is a very small amount)
- On 28 Oct Sankar had just been granted 565,000 shares (code A); this sale is about 68% of that grant
Show 6 more
- NHS Cancer 360 pilot, four years in: the official figure in Mar 2026 was 5 trusts using it (2 listed as benefiting); data in October said 6 (5 benefiting) and was later taken off the web page
- The two officially promoted success pilots (Chelsea and Westminster, Royal United Hospitals Bath) had zero logged-in users over the past 12 months, according to FOI replies
- East Lancashire is on the list of users but has only 1 user, and itself confirmed it has not gone live on the Federal Data Platform
- East Kent (no immediate need) and Bedfordshire (metadata requirements problem) declined of their own accord
- On 13 Nov the NHS took down its list of 137 beneficiaries, so the claimed results of the flagship use cases do not hold up
- Source: The Register, 13 Nov, citing official NHS England data and FOI replies
Catalysts to watch
- Follow-up insider Form 4 filings: whether receiving and then selling shares becomes a regular rhythm
- Risk of replacement before the NHS Federal Data Platform contract expires in 2029
- Whether the NHS adjusts its Cancer 360 claims further
- The next equity award approval (the 85% rise on 2 Nov is the baseline)
Risks
- The first large voluntary sale by a chief-technology-officer-level insider after earnings, on top of the 85% rise in equity awards on 2 Nov, makes the insider cycle worth tracking
- The NHS flagship healthcare platform's showcase narrative is damaged (a reputational cost for sales elsewhere)
- Low penetration of a single product on the Federal Data Platform is a hard weakness, not just political resistance
- The long-term risk of being replaced in 2029
Sources 4
- SEC EDGAR Form 4, 13 Nov (Sankar)
- The Register report, 13 Nov
- Official NHS England data and Freedom of Information (FOI) replies
- Comparison of Form 144 disclosure with actual trades on Form 4